Repros Therapeutics Inc. (RPRX) SEC Filing 8-K Material Event for the period ending Wednesday, September 13, 2017

Repros Therapeutics Inc.

CIK: 897075

View differences made from one to another to evaluate Repros Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Repros Therapeutics Inc..


Assess how Repros Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Repros Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


CIK: 897075
Form Type: 8-K Corporate News
Accession Number: 0001144204-17-048137
Submitted to the SEC: Fri Sep 15 2017 8:57:59 AM EST
Accepted by the SEC: Fri Sep 15 2017
Period: Wednesday, September 13, 2017
Industry: Biological Products No Disgnostic Substances
  1. Vote of Security Holders

External Resources:

Bookmark the Permalink: